

Release from ASX Escrow

15 November 2019, Melbourne: Rhythm Biosciences (ASX: RHY), a medical diagnostics company developing its lead product, ColoSTAT[®], as a global, low cost, simple blood test for the accurate and early detection of colorectal cancer, advises that, in accordance with ASX Listing Rule 3.10A, the following securities will be released from escrow on 7 December 2019:

No of securities	Security type
38,500,000	Fully paid ordinary shares
2,000,000	Unlisted options exercisable at 30 cents expiring 7 December 2020

For further information, please contact:

Glenn Gilbert
Chief Executive Officer
+61 3 8256 2880

About Rhythm Biosciences

ASX-listed Rhythm Biosciences is developing and commercialising a screening and diagnostic tool for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT[®], is intended to be a simple, affordable, minimally invasive and effective blood test for the early detection of bowel cancer for the global mass market. It is expected to be comparable to, if not better than, the current standard of care, the faecal immunochemical test (FIT), at a lower cost. ColoSTAT[®] also provides an alternative for those who choose not to, or are unable to, be assessed using standard screening programs.

ColoSTAT[®] is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure.

ColoSTAT[®] has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer. Globally, over 850,000 people die from colorectal cancer each year.

Rhythm Biosciences

ACN: 619 459 335
ASX: RHY

Issued Capital

100,750,000 Shares
3,504,200 Options and
Performance Shares

Australian Registered Office

Level 17, 500 Collins Street
Melbourne VIC 3000
www.rhythmbio.com

Directors

Otto Buttula – Chairman of the Board
Trevor John Lockett – Executive Director
Louis James Panaccio – Non-Executive Director
David John White – Non-Executive Director